Sign inJoin waitlistJoin the waitlist

Kathryn Torok

Director, Pediatric Systemic Scleroderma Clinic · UPMC Medical Education

Credentials: · ·

History

Pediatric Craniofacial Scleroderma Clinic · UPMC Medical Education
Present
Pediatric Craniofacial Scleroderma Center · UPMC Medical Education
Present
Pediatric Craniofacial Scleroderma Clinic · Univ of Pittsburgh Sch of Med
Present

Pediatric Rheumatology
UPMC Children's Hospital of Pittsburgh
2006–2009
Pediatrics
UPMC Children's Hospital of Pittsburgh
2004–2006
Penn State College of Medicine
2000–2004
Biology, The Pennsylvania State University
1996–2000

Research

Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study
Rheumatology · 2010 · 154 citations
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures
The Journal of Rheumatology · 2009 · 132 citations
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma
Arthritis Care & Research · 2012 · 125 citations

Suzanne Li
23 papers
Heidi Jacobe
15 papers
GH
Gloria Higgins
9 papers
Kaveh Ardalan
8 papers
Franziska Rosser
7 papers
Natalia Vasquez-Canizares
7 papers
Robert Lafyatis
6 papers
Anjali Patwardhan
5 papers
AS
Anne Stevens
5 papers
FD
Fatma Dedeoglu
5 papers
Katherine Kurzinski
5 papers · 2 as a resident
Katie Stewart
5 papers

Grants

Integrating Spatial and Single-Cell Transcriptomics with Histology to Define Endotypes in Pediatric Scleroderma
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
Contact PI · $974K · University of Pittsburgh at Pittsburgh
2025–2030
Establishing and Validating Outcome Measures for Craniofacial Morphea Across the Lifespan
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
PI · $222.4K · Ut Southwestern Medical Center
2026–2030
Ancillary Studies to Define Dysregulated Immune and Fibrotic Pathways in a Well-Characterized Morphea Cohort
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
Contact PI · $1.4M · University of Pittsburgh at Pittsburgh
2021–2025
Refining Outcome Measures Through Observational Cohorts to Advance Trials in Morphea
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
PI · $640.5K · Ut Southwestern Medical Center
2019–2023

Clinical trials

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Site PI · Recruiting · Phase 2, Phase 3
Cabaletta Bio
2023–2028
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Sub-investigator · Recruiting · Phase 2
Paul Szabolcs
2018–2028
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Sub-investigator · Recruiting
Duke University
2015–2028